A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

Brief description of study

The purpose of this first-in-human (FIH) study is to investigate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and preliminary efficacy of PRT3789 as monotherapy and in combination with Docetaxel in participants with select advanced, recurrent or metastatic solid tumors with a SMARCA4 mutation.


Clinical Study Identifier: s22-01405
ClinicalTrials.gov Identifier: NCT05639751
Principal Investigator: Salman Rafi Punekar.
Other Investigators: Nila Theresa De La Rosa, Scot Niglio, Samantha VanMaanen, Kirby Rodriguez, Jeffrey S. Weber, Kathleen M Madden, Elaine Shum, Jessica Wang, Kristen Spencer, Joshua K Sabari, Keriann M Scavone, Cosmin Adrian Tegla, Nina Beri, Nancy Chan, Vamsidhar Velcheti, Douglas K Marks, Eneil De La Pena, Janice Mehnert, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.